Eribulin
CAS 253128-41-5 2 FDA-DMF suppliersSmall Molecule
Overview
Eribulin is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1683590).
Patent & exclusivity (US)
Per the FDA Orange Book (11 approved US products), the latest listed US patent on Eribulin expires 7 Jul 2027 and exclusivity 13 Mar 2026. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one
- Canonical SMILES
- C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O
- InChIKey
- UFNVPOGXISZXJD-JBQZKEIOSA-N
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.